Drug Discovery 2022: driving the next life science revolution

TCR Evolution, revolution: How Adaptimmune is developing innovative TCR T-cell therapies to treat solid tumors

Tue4  Oct11:10am(30 mins)
Auditorium 3
Dr Jo Brewer


Adaptimmune designs, develops, and delivers T-cell therapies for solid tumors. By engineering T-cell receptors (TCRs) to a high affinity against cancer antigens, the Company has built a broad pipeline to target solid tumors. As an integrated cell therapy company, Adaptimmune uses in-house manufacturing capabilities to introduce its proprietary engineered TCRs into patient’s own T-cells, thus empowering a person’s own immune system to fight their disease. With added next-generation enhancements to improve efficacy, and a rapidly developing allogeneic program to provide off-the-shelf T-cell therapies to any eligible patient, Adaptimmune is at the forefront of immuno-oncology.

Hosted By


The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis